Over-activation of the inflammasome in patients with RIPK1 mutations may suggest that IL-1 blocking agents can be effective in suppressing the IBD phenotype, though additional pro-inflammatory cytokines and pathways may also be dysregulated and contribute to the hyper-inflammatory immune response observed in this disorder. Here, RIPK1 is linked to inflammatory bowel disease.